Phosphodiesterase 4 (PDE4) (PDE4)

Phosphodiesterase 4 is a cAMP-specific phosphodiesterase enzyme family responsible for degrading cyclic adenosine monophosphate (cAMP) within cells, thereby regulating various signal transduction pathways. PDE4 is highly expressed in immune cells and the central nervous system and plays important roles in regulating inflammation, immune function, and neuronal activity. The family consists of four main isoforms (PDE4A, PDE4B, PDE4C, PDE4D), each with distinct tissue distributions and physiological functions. Clinically, PDE4 is a validated therapeutic target, with selective inhibitors used for conditions like COPD, psoriasis, and atopic dermatitis. Research and development continue in neurological and autoimmune diseases; however, therapeutic use is challenged by notable gastrointestinal side effects, especially emesis due to the modulation of certain isoforms like PDE4D.

Other names

Type 4 phosphodiesterasePDE4cAMP-specific phosphodiesterasecAMP phosphodiesterasePDE4A, PDE4B, PDE4C, PDE4D (denoting main isoforms/subfamilies)

Inhibition of cAMP hydrolysis (most drugs act as selective inhibitors of the catalytic site, resulting in increased intracellular cAMP levels) Allosteric modulation (newer compounds may target regulatory domains, alter isoform specificity, and reduce side effects)